A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)
To compare the effectiveness of Pembrolizumab (study drug) compared to
standard of care therapies in adults with Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Carcinoma
Microsatellite Instability-High (MSI-H) stage IV Colorectal Cancer
Mismatch Repair Deficient (dMMR) stage IV Colorectal Cancer
1. Male or female age 18 or older
2. Confirmed MMR deficient (dMMR) or microsatellite instability high (MSI-H) stage IV colorectal carcinoma
3. No prior systemic therapy for stage IV colorectal cancer
Other criteria apply
18 - 100
Healthy Volunteers Needed
Duration of Participation
Treatment will continue until your disease progresses, you can’t tolerate the treatment, or you and/or your doctor decide to stop treatment. After that participants will be contacted by phone every 3 months until the end of the study.
Knight Clinical Trials Information Line
Merck Sharp & Dohme Corp.